$IONS 8-K SEC Filings

Filed On	Filing
23 Oct 2026	8-K: Regulation FD Disclosure; Other Events Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
21 Oct 2026	8-K: Regulation FD Disclosure; Other Events – Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care –
23 Sep 2026	8-K: Regulation FD Disclosure; Other Events – Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –
04 Sep 2026	8-K: Regulation FD Disclosure; Other Events
04 Sep 2026	8-K: Regulation FD Disclosure; Other Events
29 Jul 2026	8-K: Results of Operations and Financial Condition
10 Jul 2026	8-K: Regulation FD Disclosure
09 Jul 2026	8-K: Regulation FD Disclosure; Other Events
24 Jun 2026	8-K: Regulation FD Disclosure; Other Events
12 Jun 2026	8-K: Other Events
08 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
28 May 2026	8-K: Regulation FD Disclosure; Other Events
29 Apr 2026	8-K: Results of Operations and Financial Condition
21 Apr 2026	8-K: Regulation FD Disclosure; Other Events
09 Mar 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
25 Feb 2026	8-K: Results of Operations and Financial Condition
12 Jan 2026	8-K: Results of Operations and Financial Condition
07 Jan 2026	8-K: Regulation FD Disclosure; Other Events
17 Nov 2025	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
10 Nov 2025	8-K: Regulation FD Disclosure; Other Events

Comments